Vytrus advances the science of plant exosomes with awarded Innovations and patented technologies
Vytrus Biotech continues to advance the frontiers of natural plant exosomes derived from sustainable plant biotechnology, reinforcing its position as a scientific leader in next-generation skin and hair care with the latest innovations innovations:
Clarivine™ – Fasting for Skin Longevity
Recently awarded Best Innovation at in-cosmetics Global and Indonesia Cosmetic Ingredients 2025, announced by the company in this news, Clarivine™ stands as a benchmark in longevity-driven dermocosmetic science. This patented and award-winning active, developed from Vitis vinifera stem cell cultures, mimics the beneficial effects of cellular fasting to activate skin longevity pathways. Clarivine™ introduces exosomic resveratrol, encapsulated in natural plant exosomes, to target visible signs of aging and stimulate deep skin regeneration.
Centella Reversa™ – The Equation of Youth
A rejuvenating plant strategy that delivers regeneration signals to the skin from Centella asiatica stem cells. Its exosomes are rich in bioactive peptides, termed exosomic peptides, which exhibit potent anti-wrinkle effects and regenerative properties in skin care with proven anti-aging and anti-inflammatory benefits.
Capilia Longa™ – Make Your Hair Sprout Again
Formulated from Curcuma longa stem cells, Capilia Longa™ activates hair follicle recovery using genuine plant growth factors. Recent research from Vytrus highlights the presence of exosomic peptides in its exosomal fraction, further supporting its effectiveness in boosting hair density and reducing hair loss across scalp, brows, and lashes.
Extensive research continues to validate Vytrus’ portfolio of natural plant exosomes as biological communicators that deliver targeted signals to skin and hair cells — unlocking regenerative, anti-aging, and longevity mechanisms in a sustainable and efficient way.
Discover how Exosomic Resveratrol and Peptides are reshaping the future of cosmetic science by contacting the Vytrus technical team today.
Vytrus Biotech has also received its second U.S. patent grant, covering key actives from its proprietary pipeline, Clarivine™ and Centella Reversa™, for wound healing applications. This milestone further validates the global relevance of Vytrus’ technology in the cosmetic ingredient space. The patent recognizes the therapeutic potential of Vytrus’ natural plant exosomes and exosomic bioactives, in increasing demand by the dermocosmetic industry for their skin-regenerating, anti-aging, and protective properties.
Read more about this patent achievement in our published news here.
